Iclusig tablets 15mg

Iclusig (ponatinib hydrochloride) tablets, 15mg (YJ code: 4291048F1020, standard: 15mg 1 tablet), manufactured by Otsuka Pharmaceutical, are a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is used when other tyrosine kinase inhibitor (TKI) therapies are not indicated, not effective, or not toler…